<h4>Background</h4>Serum biomarkers of multiple sclerosis (MS), such as glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL), are established indicators of disease progression and disability. Here, NEFL is linked to myeloid sarcoma.